This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Arvinas‘ lead protein degrader ARV-110 to treat patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after at least two prior therapies, the company announced. Therapies that target the androgen receptor, such…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Lynparza Approved in Europe as Initial Maintenance Therapy for Some OC
This post was originally published on this site Women in the European Union with BRCA-mutated advanced ovarian cancer can now receive Lynparza (olaparib) as a first-line maintenance treatment, AstraZeneca and Merck (known as MSD outside the U.S. and Canada) announced. The European Commission’s decision follows a positive recommendation from the Committee for Medicinal Products for Human Use…
CT103A CAR T-cell Therapy Leads to Strong Anti-cancer Responses in Relapsed or Refractory Multiple Myeloma Patients, Trial Shows
This post was originally published on this site CT103A, a fully-human anti-B-cell mature antigen (BCMA) CAR T-cell therapy, leads to strong anti-cancer responses in patients with relapsed or refractory multiple myeloma, including those who relapsed after receiving prior CAR T-cell therapy, data from a trial shows. The findings were presented in a poster, titled “Clinical…
FDA Grants Fast Track Status to Immunotherapy Candidate TRQ-1501 for Some Solid Tumors, Lymphomas
This post was originally published on this site TRQ-1501, an experimental immune cell cancer therapy developed by Torque, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of certain hard-to-treat solid tumors and lymphomas. The designation is given to therapies that show potential to treat serious health conditions,…
Kisqali-Endocrine Therapy Combo Increases Overall Survival In Hormone Receptor-Positive Breast Cancer Patients, Study Shows
This post was originally published on this site A combination of endocrine therapy and the targeted therapy Kisqali (ribociclib) is more effective than endocrine therapy alone at prolonging the survival of premenopausal women who have metastatic hormone receptor-positive breast cancer, a Phase 3 clinical trial suggests. Findings from the MONALEESA-7 trial (NCT02278120) were presented during…
Forty Seven, Acerta Collaborate to Test Triple Combo Therapy on DLBCL Patients
This post was originally published on this site Forty Seven and Acerta Pharma are collaborating to test a triple combination of the investigational 5F9 plus Rituxan (rituximab) and Calquence (acalabrutinib) in patients with diffuse large B-cell lymphoma (DLBCL). The partnership builds on prior Phase 1b data that showed a combination of Forty Seven’s 5F9 and Rituxan was safe and…
Colorectal Cancer Vaccine Candidate Induces Potent Immune Responses, Interim Trial Results Show
This post was originally published on this site A single dose of PolyPEPI1018 — Treos Bio’s investigational off-the-shelf vaccine for colorectal cancer — induced promising immune responses and clinical signs of efficacy when given in combination with standard maintenance therapy in metastatic colorectal cancer patients, interim results from a Phase 1/2 trial show. The findings…
Most Prostate Cancer Patients on Active Surveillance Don’t Follow Monitoring Guidelines, Study Shows
This post was originally published on this site Most prostate cancer patients who choose to undergo active surveillance instead of treatment are not receiving the appropriate disease monitoring, bringing into question whether or not this is a safe treatment option, according to a population-based study. The study, “Population-based cohort of prostate cancer patients on active…
Sentinel Node Biopsy Feasible to Determine Spread of Early-stage OC
This post was originally published on this site A sentinel node biopsy, used to determine whether cancer has spread to lymph nodes, is a feasible way to obtain information and avoid lymph node dissection in patients with early-stage ovarian cancer, a new study shows. The study, “Sentinel-Node Biopsy in Early Stage Ovarian Cancer: Preliminary Results…
Ygalo Continues to Induce Clinically Meaningful Responses in Relapsed or Refractory Multiple Myeloma, Phase 1/2 Trials Show
This post was originally published on this site Ygalo (melflufen) combination therapy continues to lead to clinically meaningful responses, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data from Phase 1/2 trials show. The new findings were presented in two posters, titled “ANCHOR (OP-104): A Phase 1 study update of…
‘Rare Barometer’ Program Helps Eurordis Shape EU Rare Disease Policy
This post was originally published on this site People with rare diseases know that the right government policies can make a big difference in the quality of their own lives, and those of their caregivers. But most lawmakers aren’t experts in even one well-known disease — let alone the world’s estimated 7,000 rare disorders. So…
FDA Approves Herceptin Biosimilar Kanjinti for HER2-positive Breast Cancer
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Amgen and Allergan’s Kanjinti (trastuzumab-anns), a biosimilar to Genentech’s Herceptin (trastuzumab), for all indications of its reference product — including as a treatment for HER2-positive breast cancer, the companies announced. A biosimilar is a biological medical product that is nearly identical…